N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases
- 1 December 2021
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (12), 2855-2865
- https://doi.org/10.1161/atvbaha.121.316290
Abstract
While the promise of oligonucleotide therapeutics, such as (chemically modified) ASO (antisense oligonucleotides) and short interfering RNAs, is undisputed from their introduction onwards, their unfavorable pharmacokinetics and intrinsic capacity to mobilize innate immune responses, were limiting widespread clinical use. However, these major setbacks have been tackled by breakthroughs in chemistry, stability and delivery. When aiming an intervention hepatic targets, such as lipid and sugar metabolism, coagulation, not to mention cancer and virus infection, introduction of N-acetylgalactosamine aided targeting technology has advanced the field profoundly and by now a dozen of N-acetylgalactosamine therapeutics for these indications have been approved for clinical use or have progressed to clinical trial stage 2 to 3 testing. This technology, in combination with major advances in oligonucleotide stability allows safe and durable intervention in targets that were previously deemed undruggable, such as Lp(a) and PCSK9, at high efficacy and specificity, often with as little as 2 doses per year. Their successful use even the most visionary would not have predicted 2 decades ago. Here, we will review the evolution of N-acetylgalactosamine technology. We shall outline their fundamental design principles and merits, and their application for the delivery of oligonucleotide therapeutics to the liver. Finally, we will discuss the perspectives of N-acetylgalactosamine technology and propose directions for future research in receptor targeted delivery of these gene medicines.Keywords
This publication has 72 references indexed in Scilit:
- Design and Validation of a Specific Scavenger Receptor Class AI Binding Peptide for Targeting the Inflammatory Atherosclerotic PlaqueArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- RNAi-based therapeutic strategies for metabolic diseaseNature Reviews Endocrinology, 2011
- Gallic Acid Antagonizes P-Selectin–Mediated Platelet–Leukocyte InteractionsCirculation, 2005
- A Targeted Peptide Nucleic Acid To Down-Regulate Mouse Microsomal Triglyceride Transfer Protein Expression in HepatocytesBioconjugate Chemistry, 2003
- Rational Optimization of a Short Human P-selectin-binding Peptide Leads to Nanomolar Affinity AntagonistsOnline Journal of Public Health Informatics, 2003
- Novel hepatotrophic prodrugs of the antiviral nucleoside 9‐(2‐phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activityThe FASEB Journal, 2000
- Crystal Structure of the Carbohydrate Recognition Domain of the H1 Subunit of the Asialoglycoprotein ReceptorJournal of Molecular Biology, 2000
- Specific targeting of the antiviral drug 5-Iodo 2′-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysineJournal of Hepatology, 1994
- Mammalian Hepatic LectinScience, 1974
- Solubilization of hepatic binding sites for asialo-glycoproteinsBiochemical and Biophysical Research Communications, 1972